Intellia Therapeutics' Crispr-Based Treatment Achieves Success in Pivotal Trial
Intellia Therapeutics has announced that its Crispr-based treatment for hereditary angioedema has met its goals in a late-stage trial. The treatment, which edits DNA in vivo to turn off a gene causing overproduction of a peptide, reduced swelling attacks by 87% compared to a placebo. This marks a significant milestone in gene editing, as it is the first Phase 3 data for in vivo Crispr treatment. The company plans to seek FDA approval and aims to launch the treatment in the U.S. next year. 
